Citations

Clear

3138 citation(s) found for "Smith, AM".

Epilepsy with Eyelid Myoclonia: Should Focal Seizures Exclude the Diagnosis? (P11-9.012)
Siebold, Lorraine , Snehal, Isha , Britton, Jeffrey W. , Wong‐Kisiel, Lily C. , Wirrell, Elaine , Smith, Kelsey M.

Mayo Clinic

Neurology | April 7, 2025 | Volume: 104 | Issue: 7_Supplement_1 | Pages: No page available

10.1212/wnl.0000000000210823 Get It

Drug-Resistant GAD65-Associated Epilepsy: Pre-Surgical Evaluation and Comparison to Temporal Lobe Epilepsy of Other Etiology (P2-9.005)
Thomsen, Anna, Guerrero, Gloria Ortiz, Britton, Jeffrey W. , Dubey, Divyanshu , Smith, Kelsey M.

Mayo Clinic

Neurology | April 7, 2025 | Volume: 104 | Issue: 7_Supplement_1 | Pages: No page available

10.1212/wnl.0000000000211367 Get It

The Urgent Need for Evidence Over Anecdote: Equipoise in the ExTINGUISH Clinical Trial in Anti-NMDAR Encephalitis (P7-8.016)
Smith, Tammy, Peterson, Lisa K. , Ζεκερίδου, Αναστασία , Coffey, Christopher S. , Banwell, Brenda, Dialino-Felix, Annalisa, Flavin, Susan , Dill, L.V., Cho, Hyun , Day, Gregory S. , Clardy, Stacey , Clardy, Stacey L , Day, Gregory S , Hoshina, Yoji , Smith, Tammy, Wong, Ka-Ho , Aboseif, Albert , Wright, Melissa A. , Dill, Lisa, Dalmau, Josep , Titulaer, Maarten J

Mayo Clinic

Neurology | April 7, 2025 | Volume: 104 | Issue: 7_Supplement_1 | Pages: No page available

10.1212/wnl.0000000000211728 Get It

MSTO1-related Autosomal Recessive Mitochondrial Myopathy and Ataxia Syndrome: A Case Series and Description of Phenotypes (P2-6.012)
Selcen, Duygu , Smith, Benn, Sharma, Rishi , Schimmenti, Lisa A. , Smith, Benn E., Vairo, Filippo Pinto e , Dhamija, Radhika

Mayo Clinic

Neurology | April 7, 2025 | Volume: 104 | Issue: 7_Supplement_1 | Pages: No page available

10.1212/wnl.0000000000210943 Get It

Abstract 729: Tissue Specific Reductions in Sirtuin-6 Expression Affect Calcium Burden and Pro-osteogenic Signaling in the Aortic Valve
Puvvala, Sahithi , Verzosa, Grace, Huang, Runqing, Roos, Carolyn M, Smith, Leslie A, Zhang, Bin , Miller, Jordan D.

Mayo Clinic

Arteriosclerosis, Thrombosis, and Vascular Biology | April 7, 2025 | Volume: 39 | Issue: Suppl_1 | Pages: No page available

10.1161/atvb.39.suppl_1.729 Get It

Sirtuin-6 (SIRT6) is a protein deacetylase that functions in several pathways related to aging, as complete loss of SIRT6 in mice elicits multiple age-associated phenotypes and premature death. While increasing age is a major risk factor for development of calcific aortic valve disease (CAVD), it is unclear whether loss of SIRT6 accelerates aortic valve calcification. Here, we report the role of SIRT6 in a subset of aortic valve interstitial cell progenitors (neural crest-derived VICs) by crossing mice carrying Cre recombinase under the control of a PAX3 promoter with mice harboring a SIRT6 gene that can be conditionally inactivated (SIRT6 FL/+ ). We hypothesized that tissue-specific reductions of SIRT6 would increase calcification, increase pro-osteogenic signaling, and impair aortic valve function. We examined mice of the genotypes Cre-/SIRT6 FL/+ or Cre+/ SIRT6 FL/+ at two different time points: young (3 months) and old (14-24 months). First, we used qRT-PCR to demonstrate that SIRT6 was effectively reduced in the aortic valve from PAX3-cre/SIRT6 FL/FL mice. Although reductions in SIRT6 did not change aortic valve calcium (Alizarin Red) in young mice, reducing SIRT6 increased valvular calcium levels in old mice compared to their WT littermates. Interestingly, protein levels of osterix were substantially increased in young, SIRT6-deficient mice compared to WT littermates but were paradoxically decreased in old SIRT6-deficient mice. Regardless of age, histopathological, or molecular changes, we did not observe detectable changes in cusp separation distance at any time point. Collectively, these data suggest that, contrary to our hypothesis, depletion of SIRT6 in neural crest cells—which are key progenitors of valve interstitial cells—is not sufficient to impair aortic valve function. Importantly, this finding suggests that age-associated reductions in SIRT6 may be a permissive context for development of CAVD but relies heavily on the presence of additional risk factors.
Aging-dependent dysregulation of EXOSC2 is maintained in cancer as a dependency
Skamagki, Maria , Hacisuleyman, Ezgi , Galleti, Giuseppe, Vinagolu, Rajasekhar, Cha, HyoKyeong, Ata, Deniz, Kim, Jong-Jin , Weiskittel, Taylor M. , Diop, Mame, Aung, Thiri, Latto, Michael Del , Kim, Amanda S., Li, Zhuoning , Zhao, Rui , Hendrickson, Ronald C. , Bott, Matthew J. , Hu, Li , Romesser, Paul B , Smith, J Joshua , Giannakakou, Paraskevi , Zhang, Cheng, Wu, Chao , Cha, HyoKyeong, Kim, Jongjin, Diop, Mame, Aung, Thiri, Miele, Matthew M. , Tang, Laura H. , Hendrickson, Ronald C. , Romesser, Paul B. , Smith, J. Joshua , Darnell, Robert B. , Li, Hu, Kim, Kitai

Mayo Clinic

No container title available | April 7, 2025 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.1101/2025.04.04.647279 | PMID 40236131 Get It

Abstract Reprogramming of aged donor tissue cells into induced pluripotent stem cells (A-iPSC) preserved the epigenetic memory of aged-donor tissue, defined as genomic instability and poor tissue differentiation in our previous study. The unbalanced expression of RNA exosome subunits affects the RNA degradation complex function and is associated with geriatric diseases including premature aging and cancer progression. We hypothesized that the age-dependent progressive subtle dysregulation of EXOSC2 (exosome component 2) causes the aging traits (abnormal cell cycle and poor tissue differentiation). We used embryonic stem cells as a tool to study EXOSC2 function as the aging trait epigenetic memory determined in A-iPSC because these aging traits could not be studied in senesced aged cells or immortalized cancer cells. We found that the regulatory subunit of PP2A phosphatase, PPP2R5E, is a key target of EXOSC2 and this regulation is preserved in stem cells and cancer.
Enhancing Interstitial Lung Disease Diagnoses Through Multimodal AI Integration of Histopathological and CT Image Data
Lami, Kris , Ozasa, Mutsumi , Che, Xiangqian, Uegami, Wataru , Zaizen, Yoshiaki , Mori, Ichiro , Ichihara, Shin , Yoon, Han‐Seung, Kataoka, Kensuke , Johkoh, Takeshi , Kondo, Yasuhiro , Attanoos, Richard , Marchevsky, Alberto M. , Schneider, Frank , Augustyniak, Jaroslaw, Almutrafi, Amna, Roden, Anja C. , Moreira, André L. , Zaizen, Yoshiaki , Egashira, Ryoko , Fabro, Alexandre Todorovic , Che, Xiangqian, Kato, Yoshihiro , Tsuyama, Naoko , Egashira, Ryoko , Fabro, Alexandre Todorovic , Brčić, Luka , Smith, Maxwell L. , Fukuoka, Junya

Mayo Clinic

Respirology | April 4, 2025 | Volume: 30 | Issue: 8 | Pages: 726-735

10.1111/resp.70036 | PMID 40176267 Get It

ABSTRACTBackground and ObjectiveThe diagnosis of interstitial lung diseases (ILDs) often relies on the integration of various clinical, radiological, and histopathological data. Achieving high diagnostic accuracy in ILDs, particularly for distinguishing usual interstitial pneumonia (UIP), is challenging and requires a multidisciplinary approach. Therefore, this study aimed to develop a multimodal artificial intelligence (AI) algorithm that combines computed tomography (CT) and histopathological images to improve the accuracy and consistency of UIP diagnosis.MethodsA dataset of CT and pathological images from 324 patients with ILD between 2009 and 2021 was collected. The CT component of the model was trained to identify 28 different radiological features. The pathological counterpart was developed in our previous study. A total of 114 samples were selected and used for testing the multimodal AI model. The performance of the multimodal AI was assessed through comparisons with expert pathologists and general pathologists.ResultsThe developed multimodal AI demonstrated a substantial improvement in distinguishing UIP from non‐UIP, achieving an AUC of 0.92. When applied by general pathologists, the diagnostic agreement rate improved significantly, with a post‐model κ score of 0.737 compared to 0.273 pre‐model integration. Additionally, the diagnostic consensus rate with expert pulmonary pathologists increased from κ scores of 0.278–0.53 to 0.474–0.602 post‐model integration. The model also increased diagnostic confidence among general pathologists.ConclusionCombining CT and histopathological images, the multimodal AI algorithm enhances pathologists' diagnostic accuracy, consistency, and confidence in identifying UIP, even in cases where specialised expertise is limited. image
Risk of cardiovascular disease in people with narcolepsy: a plain language summary of publication
Black, Jed , Smith, R. Brian, Dabrowski, Elizabeth , Taylor, Ben , Somers, Virend K.

Mayo Clinic

Future Cardiology | April 3, 2025 | Volume: 21 | Issue: 6 | Pages: 339-348

10.1080/14796678.2025.2482383 | PMID 40176411 Get It

A Qualitative Study of the Effects of Opioids on Chronic Pain, Function, and Cognition in Community-Dwelling Older Adults
Warner, Nafisseh S. , Finnie, Dawn M., Smith, Jamie, Verdoorn, Brandon P. , Tung, Ericka E. , Griffin, Joan M. , Griffin, Joan M , Warner, Nafisseh , Smith, Jamie L , Warner, David O. , Mielke, Michelle M.

Mayo Clinic

Journal of Applied Gerontology | April 1, 2025 | Volume: 44 | Issue: 12 | Pages: 1939-1949

10.1177/07334648251326347 | PMID 40167777 Get It

Chronic pain is common with aging. Yet, little is known about the attitudes, beliefs, and experiences of older adults with chronic pain regarding opioids, particularly in regard to effects on daily functioning and cognition. This qualitative analysis employed semi-structured interviews in 25 community-dwelling older adults with chronic pain and current or recent prescription opioid use. Interviews focused on perceptions, beliefs, and experiences of living with chronic pain, use of prescription opioids, and the impact of opioids on pain control, cognition, and daily function. Older adults display adaptability and acceptance in living with chronic pain, desire person-centered pain care, approach the risks-benefits of opioids with regards to cognition differently, and perceive stigma as a barrier to effective partnership with clinicians.
Activin A Antagonism with Follistatin Reduces Kidney Fibrosis, Injury, and Cellular Senescence-Associated Inflammation in Murine Diabetic Kidney Disease
Bian, Xiaohui , Snow, Zachary K. , Zinn, C. , Gowan, Cody, Conley, Sabena M., Bratulin, Anastasia L. , Elhusseiny, Khaled , Miller, Jordan D. , Kirkland, James L. , Lerman, Lilach O. , Zinn, Caroline J, Gowan, Cody C , Elhusseiny, Khaled M , Miller, Jordan , Kirkland, James L , Lerman, Lilach O , Smith, Anastasia , Bian, Xiaohui , Tchkonia, Tamar , Hickson, LaTonya J.

Mayo Clinic

Kidney360 | March 30, 2025 | Volume: 6 | Issue: 8 | Pages: 1278-1291

10.34067/kid.0000000776 | PMID 40152935 Get It

Key Points Activin A is implicated in profibrotic and prosenescent kidney injury and correlates with kidney injury markers in animals and humans. Follistatin, through activin A antagonism, reduces senescence burden, macrophage infiltration, and proinflammatory pathway activation in murine diabetic kidney disease. Follistatin and other antagonists of activin A signaling pathways may be promising, novel therapeutics for diabetic kidney disease. Background Circulating activin A, an inflammatory mediator implicated in profibrotic kidney injury and cellular senescence-induced adipose tissue dysfunction, is increased in human diabetic kidney disease (DKD) and directly correlates with kidney dysfunction. We tested the hypothesis that activin A increases kidney injury, senescent cell abundance, and macrophage infiltration in DKD and antagonism through follistatin (FS) therapy diminishes these effects. Methods An accelerated nephropathy type 2 diabetes (db/db) mouse model was generated by implantation of angiotensin II-loaded osmotic minipumps resulting in increased albuminuria and glomerular and tubular injury. Kidney repair effects of FS (5 µ g intraperitoneal; two doses) were assessed through markers of kidney injury, fibrosis, inflammation, cellular senescence, and macrophage infiltration. In vitro studies examined antiactivin effects of FS on high glucose-exposed human monocytes, renal fibroblasts, and renal tubule epithelial cells. Results Activin A antagonism with FS reduced senescence (p19), proinflammatory (including senescence-associated secretory phenotype), and profibrotic markers including activin A. FS improved kidney morphology, restored podocyte markers (nephrin and Wilms tumor-1), and reduced kidney injury biomarkers, albuminuria and kidney fibrosis. FS decreased kidney macrophage and leukocyte infiltration and absent in melanoma 2 inflammasome activation. FS seemed to suppress inflammation through the toll-like receptor-4/NF kappa-light-chain-enhancer of activated B cells pathway in vivo further supported in human macrophages in vitro . In addition, FS reduced hyperglycemia-induced renal fibroblast activation and renal tubule epithelial cell senescence in vitro . Conclusions Activin A is a mediator of kidney injury through macrophage-associated inflammation in murine DKD. FS acts through senomorphic activities which inhibit profibrotic, proinflammatory, and prosenescence signaling by activin A. Hence, antiactivin targeting may aid in the development of a promising, novel therapeutic for DKD.